


OBERON SCIENCES

Next Generation Personalized Medicine

Improving Product Efficacy by Overcoming Adaptation

- Increase market share by improving existing product efficacy
- No development required
- Market **Product+** within 4 months

Experienced Leadership




The Challenges

- Adaptation leads to loss of effect
- No integration of subject + product + disease parameters
- Loss of effect of chronic medications / medical devices
- A plateau effect following continuous training
- Weight regain following diets



Expanding the Market



“If resistance could be overcome, the impact on survival would be highly significant”

Oberon's AI Platform:


Overcoming Adaptation to Chronic Use




*Product+ = Existing Product & Oberon's AI platform

Oberon's AI Platform:

Increasing Market Share by Improving Efficacy





Oberon's AI Platform



Oberon's AI Platform

Translating established physiological mechanisms into personalized regimens


- Preclinical data




- Clinical data

- **“Neurohormonal signaling mechanisms frequently exhibit racial differences...these differences play a role in differences in drug or device response.”**
- **“With the same drug concentration at the site of action, significant differences in the response have been observed in older patients as compared to younger patients.”**
- **“Dose adjustment during opioid therapy may not alter long-term clinical pain score...individualized opioid therapy based on clinical effectiveness should be considered to optimize treatment outcome.”**
- **“It is important to take into account size and age as well as co-morbidities in determining the appropriate drug regiment for females, as well as males.”**

<https://www.ncbi.nlm.nih.gov/pubmed/21495972>
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302116/>
<https://www.ncbi.nlm.nih.gov/pubmed/18929073>
<https://www.ncbi.nlm.nih.gov/pubmed/23452826>



Oberon's Drug+ Platform



My Physician's Guidelines

OBERON SCIENCES
Next Generation Personalized Medicine

Keppra+


Keppra+ Maximal Daily Dose 3000

Keppra+ Minimum Daily Dose 2000

Keppra+ Maximum Daily Dosages 3

Keppra+ Minimum Daily Dosages 1

I want to improve my response to Keppra+



My Daily Keppra+

OBERON SCIENCES
Next Generation Personalized Medicine

Keppra+


Aug 30, 2017 14:51:56

At 07:00 Take 500mg I TOOK MY KEPPRA+

At 14:00 Take 500mg I TOOK MY KEPPRA+

At 21:30 Take 1200mg I TOOK MY KEPPRA+

I want to improve my response to Keppra+



Home Page

OBERON SCIENCES
Next Generation Personalized Medicine

Keppra+

Welcome patient123

I HAD A SEIZURE

I FEEL SIDE EFFECTS

I cannot take my Keppra+ between 23:15 and 6:15

I want to improve my response to Keppra+

Personal Treatment Plan

Continuously changes based on: Patient input + Physician's guidelines + Database

Drug+ B2B

- **Immediate Route**

- Within approved therapeutic window
- (optional) Post marketing POC
- NO regulatory approval required

- **Trial Route**

- Outside therapeutic window
- Phase III trial → regulatory approval

- **Novel Route**

- Universal adjuvant +/- organ stimulation device
- Phase IIB trial
- Phase III trial → regulatory approval




Business Model

- License to Oberon's Platform
- License for Oberon's Clinically Insightful database

Oberon's Wearable Platform

- Most patients who lose weight gain it back
- External Vagus nerve stimulation → control “the hunger hormone” (Ghrelin)
- Using deep-learning Oberon Wearable personalizes stimuli → overcome adaptation



Obesity kills: 5th cause of mortality
Global annual cost: \$2 Trillion

Wearable B2C

- Launch as consumer product
- Monthly Subscription
- Regulatory considerations:
 - Not anticipating “medical device” classification
 - Europe CE-1 marking, FDA 510(k)



Wearable controlled by
Mobile app
24/7 call center service




12 minutes
twice a day


Oberon's SmartFit Platform

- Shorter & more effective work out sessions
- Focus on target organ-brain connection
- Differential training 2.0

B2B
Sync equipment with Oberon's Platform




Proposed Action Items: A Short Time to Market



Intellectual Property

- Closed loop organ stimulation (2016)
- Devices for gastrointestinal stimulation (2016)
- A subject-specific system and method for prevention of body adaptation for chronic treatment of disease (2017)
- A subject-tailored continuously developing randomization based algorithm for improving organ function (2017)

Milestones



Unique Investment Opportunity

- Increase market share by improving clinical efficacy
- Address unmet needs of multi billion dollar markets
- Short time-to-market
- Strong IP
- Highly experienced team
- Low risk investment, high ROI potential

Thank You!

Contact: Dr. Tahel Ilan Ber

+972-523-803463

tahel.ilanber@oberon-sci.com